Drug Trial Radar · NCT05109390
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Nov 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jul 27, 2018
Primary completion
Oct 17, 2018
Study completion Oct 17, 2018
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Achillion, a wholly owned subsidiary of Alexion
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a 3-part study with each part being an open-label, fixed-sequence, 2-period study in healthy adult participants.
Conditions
- Healthy
Interventions
DanicopanDrug
Oral tablet.
CyclosporineDrug
Oral capsule.
TacrolimusDrug
Oral capsule.
Calcium CarbonateDrug
Chewable tablet.
Aluminum/Magnesium Hydroxide/SimethiconeDrug
Chewable tablet.
OmeprazoleDrug
Oral, delayed-release capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Cyclosporine Maximum Observed Concentration (Cmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 72 hours postdose
- Part 1: Cyclosporine Time To Reach The Maximum Observed Concentration (Tmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 72 hours postdose
- Part 1: Cyclosporine Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 72 hours postdose
- Part 2: Tacrolimus Cmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 144 hours postdose
- Part 2: Tacrolimus Tmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 144 hours postdose
- Part 2: Tacrolimus AUC0-inf Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 144 hours postdose
- Part 3: Steady-state Omeprazole Cmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 24 hours postdose
- Part 3: Steady-state Omeprazole Tmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 24 hours postdose
- Part 3: Steady-state Omeprazole Area Under The Concentration-time Curve From Time 0 To The 24-hour Time Point (AUC0-24) Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 24 hours postdose
- Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Multiple-dose OmeprazoleTime frame: Up to 8 hours postdose
- Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Multiple-dose OmeprazoleTime frame: Up to 8 hours postdose
- Part 3: Steady-state Danicopan Area Under The Concentration-time Curve From Time 0 To The 8-hour Time Point (AUC0-8) Alone Versus In The Presence Of Multiple-dose OmeprazoleTime frame: Up to 8 hours postdose
- Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/SimethiconeTime frame: Up to 8 hours postdose
- Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/SimethiconeTime frame: Up to 8 hours postdose
- Part 3: Steady-state Danicopan AUC0-8 Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/SimethiconeTime frame: Up to 8 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.